4500 Background: In the first interim analysis of the randomized, multicenter, open-label,
phase 3 KEYNOTE-426 study (NCT02853331), treatment with pembro+ axi significantly …

LBA4501 Background: At the first interim analysis of the randomized, open-label, phase 3
KEYNOTE-426 (NCT02853331) study, 1L pembro+ axi showed statistically significant OS …

Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed
superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell …

5001 Background: The randomized, open-label, phase 3 KEYNOTE-426 study
(NCT02853331) demonstrated that pembrolizumab (pembro)+ axitinib (axi) significantly …

PURPOSE Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-
agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 …

The therapeutic landscape for advanced clear cell renal cell carcinoma (ccRCC) is rapidly
evolving with improved knowledge of the biology of disease leading to the incorporation of a …

5008 Background: LEN, a multikinase VEGFR inhibitor, plus everolimus is approved for
advanced RCC after prior VEGF-targeted therapy. PEMBRO, an anti-PD-1 antibody, plus …

There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma …

PURPOSE Programmed death 1 (PD-1) pathway inhibitors have not been prospectively
evaluated in patients with non–clear cell renal cell carcinoma (nccRCC). The phase II …